Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Novel Approaches for Minimizing Drug-Induced QT Interval Lengthening
NCT04675788Phase 4Completed
- Sponsor
- Indiana University
- Start
- Sep 2021
- Primary completion
- Apr 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of progesterone and Testosterone TEPI patch in long QT syndrome (LQTS) (4 arms), sponsored by Indiana University. Primary endpoints: Pre-ibutilide QT-F and QT-Fram intervals, Maximum post-ibutilide QT-F and QT-Fram intervals and 10 more. Started Sep 2021; status: completed.
02
Drugs
progesteroneTestosterone TEPI patch
03
Conditions
long QT syndrome (LQTS)
Beyond the preview
Go deeper on NCT04675788.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04675788.